GGrantIndex
← Search

PHASE I TRIAL OF BIZELESIN IN PATIENTS WITH ADVANCED CANCER

$0M01FY2000RRNIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications & trials

Abstract

The goals of this study are to define the maximum tolerated dose (MTD) of bizelesin administered as an IV push every 4 weeks; to describe the toxicities of bizelesin given on this schedule; to characterize the pharmacokinetics of bizelesin on this schedule; and to look for any evidence of antineoplastic activity of bizelesin.

View original record on NIH RePORTER →